TrialBritish journal of clinical pharmacology2019

Target engagement and cellular fate of otelixizumab: a repeat dose escalation study of an anti-CD3ε mAb in new-onset type 1 diabetes mellitus patients.

Georgios Vlasakakis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.